Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Receivables: 2015-2024

Historic Receivables for Sunshine Biopharma (SBFM) over the last 7 years, with Dec 2024 value amounting to $3.9 million.

  • Sunshine Biopharma's Receivables rose 29.11% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year increase of 19.76%. This contributed to the annual value of $3.9 million for FY2024, which is 51.56% up from last year.
  • As of FY2024, Sunshine Biopharma's Receivables stood at $3.9 million, which was up 51.56% from $2.6 million recorded in FY2023.
  • Over the past 5 years, Sunshine Biopharma's Receivables peaked at $3.9 million during FY2024, and registered a low of $1,916 during FY2020.
  • Over the past 3 years, Sunshine Biopharma's median Receivables value was $2.6 million (recorded in 2023), while the average stood at $2.8 million.
  • Data for Sunshine Biopharma's Receivables shows a peak YoY spiked of 24,421.07% (in 2022) over the last 5 years.
  • Over the past 5 years, Sunshine Biopharma's Receivables (Yearly) stood at $1,916 in 2020, then skyrocketed by 306.99% to $7,798 in 2021, then spiked by 24,421.07% to $1.9 million in 2022, then spiked by 33.48% to $2.6 million in 2023, then soared by 51.56% to $3.9 million in 2024.